Camurus AB
7CA
Company Profile
Business description
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
Contact
Ideon Science Park
LundSE-223 70
SWET: +46 462865730
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
280
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,020.20 | 13.10 | 0.15% |
| CAC 40 | 8,149.50 | 18.65 | -0.23% |
| DAX 40 | 24,490.41 | 139.29 | 0.57% |
| Dow JONES (US) | 48,063.29 | 303.77 | -0.63% |
| FTSE 100 | 9,931.38 | 9.33 | -0.09% |
| HKSE | 25,717.42 | 86.88 | 0.34% |
| NASDAQ | 23,241.99 | 177.09 | -0.76% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,845.50 | 50.74 | -0.74% |
| S&P/ASX 200 | 8,713.60 | 12.90 | 0.15% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |